Clinical Trial Update: A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with systemic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata
• Focal Segmental Glomerulosclerosis
• Systemic Lupus Erythematosus

Drugs mentioned

• VIS171

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA) | Phase 1 | Status: RECRUITING